InflaRx N.V. (IFRX) is a Biotechnology company in the Healthcare sector, currently trading at $1.21. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is IFRX = $2 (+65.3% upside).
Valuation: IFRX trades at a trailing Price-to-Earnings (P/E) of -1.4 (S&P 500 average ~25).
Financials: revenue is $28,173, +39.9%/yr average growth. Net income is $44M (loss), growing at -20.3%/yr. Net profit margin is -155584.2% (negative). Gross margin is -26108.5% (-25364.8 pp trend).
Balance sheet: total debt is $897,532 against $42M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 4.13 (strong liquidity). Debt-to-assets is 1.6%. Total assets: $55M.
Analyst outlook: 12 / 15 analysts rate IFRX as buy (80%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 0/100 (Fail), Future 94/100 (Pass), Income 10/100 (Fail).
